Other languages Amgen Inc.

Equities

AMGN

US0311621009

Market Closed - Nasdaq Other stock markets 16:00:01 2024-05-31 EDT			5-day change	1st Jan Change
305.8 ^USD	+1.59%		-0.01%	+6.17%

05-28	US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	RE
05-28	Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen : 2024 Annual Meeting of Stockholders Presentation	05-31
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	05-27
Amgen : An Underrecognized Risk Factor for Heart Disease	05-23
Improving treatment responses to solid tumours with trispecific TCEs	05-23
Amgen : From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation	05-22
Sandoz : AMM pour Wyost et Jubbonti dans l'UE	05-22
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	05-22
Amgen : Actress and Producer Gina Torres Urges Hispanic Americans to Prioritize Cholesterol Care	05-21
Amgen : At Milken Global Conference, Bradway Calls for Protecting U.S. Policy Ecosystem That Fosters Innovation	05-20
Driving Long-Term Growth: IMDELLTRA™ Approval and Information Update Presentation	05-20
Transcript : Amgen Inc. - Special Call	05-20
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-20
AMGEN - NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE TO HELP PATIENTS LIVING WITH COPD	05-20
HSBC Adjusts Price Target on Amgen to $356 From $322	05-20
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	05-20
Amgen And Sandoz Settle Denosumab BPCIA Litigation	05-20
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	05-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amgen Inc.

Equities

AMGN

US0311621009

Other languages

Filters